BioHarvest Sciences Q1 Revenue Up 8% to $8.5M; CDMO Revenue +135%
BioHarvest Sciences reported an 8% year-over-year increase in Q1 2026 revenue to $8.5 million, with gross margins improving to 59%. The company's CDMO business saw significant growth, with revenue up 135% YoY, driven by successful milestones in fragrance and saffron projects, securing over $2 million in new Stage 2 contracts. The VINIA brand's customer base grew to 90,000 active users, and the new Blood Flow Hydration product generated $920,000 in cumulative revenue. The company maintains its annual revenue guidance of $42-$48 million.
Key Highlights
- Q1 2026 total revenue increased 8% year-over-year to $8.5 million.
- CDMO revenue grew 135% year-over-year in Q1 2026.
- Secured a $1.2 million Stage 2 contract for a rare fragrance plant development.
- Signed a Stage 2 agreement valued over $1 million for saffron bioactive compounds.
- VINIA brand customer base reached 90,000 active users by end of April.
- VINIA Blood Flow Hydration product generated $920,000 in cumulative revenue.
- Net loss for Q1 2026 was $2.6 million, compared to $2.3 million last year.
- Cash and cash equivalents totaled $20.2 million as of March 31, 2026.
Price Impact
More from BHST
BioHarvest Sciences to Present at 2026 BIO International Convention
BioHarvest Sciences Q1 Net Loss $2.64M; Revenue $8.51M; Going Concern
BioHarvest Sciences Appoints Nedira Salzman-Frenkel as VP of Business Development